Continuous hyperthermic peritoneal perfusion with cisplatin for the treatment of peritoneal mesothelioma

Cancer Journal from Scientific American

Volumn 3, Issue 3, 1997, Pages 174-179

  Ma, Grace Y ^a   Bartlett, David L ^a   Reed, Eddie ^a   Figg, William D ^a   Lush, Richard M ^a   Lee, Kang Bo ^a   Libutti, Steven K ^a   Alexander, H Richard ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

cisplatin; Hyperthermia; mesothelioma; peritoneal perfusion

Indexed keywords

CISPLATIN;

ADOLESCENT; ADULT; ARTICLE; ASCITES; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERTHERMIA; INTRAPERITONEAL DRUG ADMINISTRATION; LAPAROTOMY; LEUKOPENIA; MALE; NAUSEA; PERITONEUM MESOTHELIOMA; PRIORITY JOURNAL; THROMBOCYTOPENIA; VOMITING; WOUND INFECTION;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; CISPLATIN; COMBINED MODALITY THERAPY; FEMALE; HUMANS; HYPERTHERMIA, INDUCED; MALE; MESOTHELIOMA; MIDDLE AGED; PERITONEAL NEOPLASMS; TREATMENT OUTCOME;

EID: 0030921469     PISSN: 10814442     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. McDonald AD, McDonald JC. Epidemiology of malignant mesothelioma. In: Antman K, Aisner J, eds. Asbestos-Related Malignancy. Orlando, FL: Grune & Stratton, 1987:31-55.
2. Brenner J, Sordillo PP, Magill BG et al. Malignant peritoneal mesorhelioma: a review of 25 patients. Am J Gastroenterol 1981; 75:311-313.
3. Chahinian AP, Pajak T, Holland J et al. Diffuse malignant mesothelioma: prospective evaluation of 69 patients. Ann Intern Med 1982;96:746-755.
4. van Gelder T, Hoogsteden HC, Versnel MA et al. Malignant peritoneal mesothelioma: a series of 19 cases. Digestion 1989;43: 222-227.
5. Plaus WJ. Peritoneal mesothelioma. Arch Surg 1988;123:763-766.
6. Asensio JA, Goldblatt P, Thomford NR. Primary malignant peritoneal mesothelioma. Arch Surg 1990;125:1477-1481.
7. Moertel C. Peritoneal mesothelioma. Gastroenterology 1972;63: 346-350.
8. Antman K, Osteen R, Klegar K et al. Early peritoneal mesothelioma: treatable malignancy. Lancet 1985;1:977-982.
9. Fujimoto S, Shgrestha RD, Kokubun M et al. Intraperitoneal hyperthermic perfusion combined with surgery effective for gastric cancer patients with peritoneal seeding. Ann Surg 1988;208:36-41.
10. Koga S, Hamazoe R, Maeta M et al. Prophylactic therapy for peritoneal recurrence of gastric cancer by continuous hyperthermic peritoneal perfusion with mitomycin C. Cancer 1988;61:232-237.
11. Fujimura T, Yonemura Y, Fushida S et al. Continuous hyperthermic peritoneal perfusion for the treatment of peritoneal dissemination in gastric cancers and subsequent second-look operation. Cancer 1990;65:65-71.
12. Barlogie B, Corry PM, Drewinko B. In vitro thermochemotherapy of human colon cancer cells with cis-dichlorodiammine-platinum(II) and mitomycin C. Cancer Res 1980;40:1165-1168.
13. Kitamura K, Kuwano H, Matsuda H et al. Synergistic effects of intratumor administration of cis-diamminedichloroplatinum(II) combined with local hyperthermia in melanoma bearing mice. J Surg Oncol 1992;51:188-194.
14. Howell SB, Pfeifle CG, Wung WE et al. Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Intern Med 1982;97: 45-851.
15. Howell SB, Pfeifle CE, Wung WE et al. Intraperitoneal cis-diamminedichloroplatinum with systemic thiosulfate protection. Cancer Res 1983;43:1426-1431.
16. Antman KH, Pass HI, Delaney T et al. Benign and malignant mesothelioma. In: De Vita VT, Jr., Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. Philadelphia: Lippincott, 1993:1489-1508.
17. Legha SS, Muggia FM. Pleural mesothelioma: clinical features and therapeutic implications. Ann Intern Med 1977;87:613-621.
18. Rose RG, Palmer JD, Lougheed MN. Treatment of peritoneal mesothelioma with radioactive colloidal gold. Cancer 1955;8: 478-481.
19. Kirmani S, Cleary SM, Mowry J et al. Intracavitary cisplatin for malignant mesothelioma; an update. Proceedings of ASCO 1988;5:273.
20. Markman M, Cleary S, Pfeifle C et al. Cisplatin administered by the intracavitary route as treatment for malignant mesothelioma. Cancer 1986;58:18-21.
21. Markman M, Kelsen D. Intraperitoneal cisplatin and mitomycin as treatment for malignant peritoneal mesothelioma. Regional Cancer Treatment 1989;2:49-53.
22. Spratt JS, Adcock RA, Muskovin M et al. Clinical delivery system for intraperitoneal hyperthermic chemotherapy. Cancer Res 1980; 40:256-260.
23. Fujimura T, Yonemura Y, Muraoka K et al. Continuous hyperthermic peritoneal perfusion for the prevention of peritoneal recurrence of gastric cancer: randomized controlled study. World J Surg 1994;18:150-155.
24. Gilly FN, Carry PY, Sayag AC et al. Regional chemotherapy (with mitomycin C) and intra-operative hyperthermia for digestive cancers with peritoneal carcinomatosis. Hepatogastroenterology 1994; 41:124-129.
25. Alexander HR, Buell JF, Fraker DL. Rationale and clinical status of continuous hyperthermic peritoneal perfusion for the treatment of peritoneal carcinomatosis. In: DeVita VT, Jr., Hellman S, Rosenberg SA, eds. Principles and Practice of Oncology: PPO Updates. Philadelphia: Lippincott, 1995:1-9.